Highlights of December 2022 EMA Management Board Meeting
In addition, the Clinical Trials Regulation is set to become a single-entry point for sponsors and regulators in January 2023 for the submission and assessment of all new clinical trials.
The management board of the European Medicines Agency (EMA) meet on December 14–15, 2022 in Amsterdam to discuss recent activities related to the response to COVID-19, including seven vaccines, four adapted vaccines, and eight treatments authorized for use in the European Union.
The meeting went into detail about multiple topics, such as a new budget and updated multiannual programming document for 2023–2025, which looks at looking at the growing workload from COVID-19 and the availability of resources.
In addition, the Clinical Trials Regulation is set to become a single-entry point for sponsors and regulators in January 2023 for the submission and assessment of all new clinical trials.
The Committee for Advanced Therapies Report also presented key highlights and achievements of the Committee from 2017-2022 to the Board. The Board took time to acknowledge the work of the Committee in the last 6 years and its continued efforts to support developers through the production of guidance documents and the organization of workshops and training.
Source: European Medicines Agency
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
